SANDOZ INC

Lobbying for SANDOZ INC · Pharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · $140,000.00 expenses · posted Apr 20, 2026

Lobbying activity 1

Medicare/Medicaid

Policies related to the ASP calculation in Medicare Part B Promoting a resilient pharmaceutical supply chain Policies related to serial patent litigation under the Hatch-Waxman Act. Issues related to increasing access to generic and biosimilar medications

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.